These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34387280)

  • 1. Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy.
    Jacquet A
    Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):569-575. PubMed ID: 34387280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant.
    Leonard C; Montamat G; Davril C; Domingues O; Hunewald O; Revets D; Guerin C; Blank S; Heckendorn J; Jardon G; Hentges F; Ollert M
    Allergy; 2021 Jul; 76(7):2153-2165. PubMed ID: 33345329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of engineered allergen-specific immunotherapy vaccines.
    Focke-Tejkl M; Valenta R
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):555-63. PubMed ID: 22885888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance.
    Montamat G; Leonard C; Poli A; Klimek L; Ollert M
    Front Immunol; 2021; 12():590054. PubMed ID: 33708195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells.
    Alberca-Custodio RW; Faustino LD; Gomes E; Nunes FPB; de Siqueira MK; Labrada A; Almeida RR; Câmara NOS; da Fonseca DM; Russo M
    Front Immunol; 2020; 11():692. PubMed ID: 32391011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel vaccines for allergen-specific immunotherapy.
    Akinfenwa O; Rodríguez-Domínguez A; Vrtala S; Valenta R; Campana R
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):86-99. PubMed ID: 33369572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice.
    Peng Z; Wang H; Mao X; HayGlass KT; Simons FE
    Int Immunol; 2001 Jan; 13(1):3-11. PubMed ID: 11133829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
    Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
    Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-based immunotherapeutics for the treatment of allergic disease.
    Horner AA; Van Uden JH; Zubeldia JM; Broide D; Raz E
    Immunol Rev; 2001 Feb; 179():102-18. PubMed ID: 11292014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors.
    Parronchi P; Brugnolo F; Annunziato F; Manuelli C; Sampognaro S; Mavilia C; Romagnani S; Maggi E
    J Immunol; 1999 Dec; 163(11):5946-53. PubMed ID: 10570281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
    Valenta R; Campana R; Focke-Tejkl M; Niederberger V
    J Allergy Clin Immunol; 2016 Feb; 137(2):351-7. PubMed ID: 26853127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine.
    Qiu Z; Xing L; Zhang X; Qiang X; Xu Y; Zhang M; Zhou Z; Zhang J; Zhang F; Wang M
    Oncol Rep; 2017 Jun; 37(6):3441-3448. PubMed ID: 28498413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant allergens for immunotherapy: state of the art.
    Zhernov Y; Curin M; Khaitov M; Karaulov A; Valenta R
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):402-414. PubMed ID: 31082821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.
    Kovarik J; Bozzotti P; Love-Homan L; Pihlgren M; Davis HL; Lambert PH; Krieg AM; Siegrist CA
    J Immunol; 1999 Feb; 162(3):1611-7. PubMed ID: 9973420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model.
    Wai CYY; Leung NYH; Leung PSC; Chu KH
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice vaccinated with allergen-pulsed myeloid dendritic cells are not protected from developing allergen-induced Th2 responses.
    Trujillo-Vargas CM; Ramirez-Pineda JR; Palmetshofer A; Grunewald S; Moll H; Berberich C; Erb KJ
    Int Arch Allergy Immunol; 2005 Jul; 137(3):219-28. PubMed ID: 15956790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant allergens for immunotherapy. Where do we stand?
    Niederberger V; Valenta R
    Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):549-54. PubMed ID: 15640698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.